US-based ResMed and New Zealand-based Fisher & Paykel Healthcare have reached an agreement to settle all patent infringement litigations across all regions worldwide.

The companies have been in dispute over patent infringement since 2016 in multiple countries, including the US, New Zealand and Australia.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Their recent litigation involved a claim filed by ResMed against Fisher & Paykel Healthcare, seeking a ban on import and sale of Fisher & Paykel’s Simplus full face, Eson nasal and Eson 2 nasal masks in the US.

“Under the terms of the latest agreement, all ongoing proceedings will be dismissed. The settlement does not involve any payment or admission of liability by either party.”

Due to the settlement, no further infringement proceedings will be conducted against ResMed products such as AirSense flow generators, AirFit P10, Swift LT and Swift FX masks and ClimateLine heated tubes.

This also applies to Fisher & Paykel Healthcare products, including Simplus, Eson and Eson 2 masks

Fisher & Paykel Healthcare CEO Lewis Gradon said: “We are pleased to bring these disputes to a close and we appreciate the support of our customers and shareholders throughout the process.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“The intellectual property we have generated through our investment in R&D over the past 50 years has enabled us to positively impact the lives of many millions of patients.”

Under the terms of the latest agreement, all ongoing proceedings will be dismissed. The settlement does not involve any payment or admission of liability by either party.

Each company will bear its own attorney fees and costs incurred in the global proceedings.

ResMed CEO Mick Farrell said: “This agreement supports the best interests of ResMed, and all of our stakeholders, including patients, providers, physicians, and shareholders.

“We will defend our intellectual property wherever necessary to ensure that our mask, device and software customers receive the innovative solutions they deserve.”

Both ResMed and Fisher & Paykel Healthcare develop medical devices to help in respiratory care.

The settlement between the two firms is effective immediately, and both companies have requested the withdrawal of the pending cases.

Additional reporting by Charlotte Edwards. 

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact